Gregory B. Brown, MD

Greg Brown, Lisata Board of Directors
Gregory B. Brown, MD, Lisata Board of Directors

Gregory B. Brown, M.D. was appointed to the Company’s Board in October 2016 and was elected Chairman on February 16, 2017. Dr. Brown is currently Chief Executive Officer of Memgen, Inc., a development-stage biotechnology company. In 2007, Dr. Brown co-founded and remains Vice Chairman of HealthCare Royalty Partners (“HCR Partners”), a healthcare-focused private asset management firm investing in biopharmaceutical and medical products and developing and deploying innovative risk-mitigated investment strategies to deliver non-correlated cash flow. Dr. Brown was educated as a transplantation immunologist and trained as a thoracic and vascular surgeon. He practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical and medical evaluation of products as well as in healthcare systems and payor/reimbursement dynamics. He has been involved in sourcing, performing due diligence on and closing more than $1 billion of royalty financings.

Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves on the boards of FAST Biomedical since January 2020, Memgen, Inc. since October 2018, and Aquestive Therapeutics, Inc. since 2017. He previously served on the boards of Cambrex Corporation, Faron Pharmaceuticals, Oy, Invuity, Inc. and Vanderbilt Clinical, S.a.r.l. The Lisata Board has concluded that Dr. Brown should continue serving as Chairman based on his medical, financial and management experience.